|
HY-N3102A-25mg
|
MedChemexpress LLC
|
(E)-p-Coumaryl alcohol [CAS 20649-40-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N3102A-5mg
|
MedChemexpress LLC
|
(E)-p-Coumaryl alcohol [CAS 20649-40-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-N3102A-50mg
|
MedChemexpress LLC
|
(E)-p-Coumaryl alcohol [CAS 20649-40-5]
|
|
COVID-19-immunoregulation
|
|
|
HY-109785A-1mg
|
MedChemexpress LLC
|
(R)-Gyramide A (hydrochloride) [CAS 1793050-70-0]
|
|
|
|
|
HY-N1356A-1mg
|
MedChemexpress LLC
|
(R)-Reticuline [CAS 3968-19-2]
|
|
|
|
|
HY-N1356A-5mg
|
MedChemexpress LLC
|
(R)-Reticuline [CAS 3968-19-2]
|
|
|
|
|
HY-135336-10mg
|
MedChemexpress LLC
|
(R)-Verapamil (hydrochloride) [CAS 38176-02-2]
|
|
Cancer-programmed cell death
|
|
|
HY-135336-100mg
|
MedChemexpress LLC
|
(R)-Verapamil (hydrochloride) [CAS 38176-02-2]
|
|
Cancer-programmed cell death
|
|
|
HY-135336-5mg
|
MedChemexpress LLC
|
(R)-Verapamil (hydrochloride) [CAS 38176-02-2]
|
|
Cancer-programmed cell death
|
|
|
HY-135336-50mg
|
MedChemexpress LLC
|
(R)-Verapamil (hydrochloride) [CAS 38176-02-2]
|
|
Cancer-programmed cell death
|
|
|
HY-135336-1mL
|
MedChemexpress LLC
|
(R)-Verapamil (hydrochloride) [CAS 38176-02-2] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-Y1108-10g
|
MedChemexpress LLC
|
(S,S)-TsDPEN [CAS 167316-27-0]
|
|
|
|
|
HY-Y1108-5g
|
MedChemexpress LLC
|
(S,S)-TsDPEN [CAS 167316-27-0]
|
|
|
|
|
HY-13212-10mg
|
MedChemexpress LLC
|
(Z)-2-Decenoic acid [CAS 15790-91-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13212-5mg
|
MedChemexpress LLC
|
(Z)-2-Decenoic acid [CAS 15790-91-7]
|
|
Cancer-programmed cell death
|
|
|
HY-13212-1mL
|
MedChemexpress LLC
|
(Z)-2-Decenoic acid [CAS 15790-91-7] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
|
HY-P1159A-10mg
|
MedChemexpress LLC
|
[D-p-Cl-Phe6,Leu17]-VIP (TFA)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1159A-5mg
|
MedChemexpress LLC
|
[D-p-Cl-Phe6,Leu17]-VIP (TFA)
|
|
COVID-19-immunoregulation
|
|
|
HY-P1012A-1mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P (TFA) [CAS 2828433-10-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012A-10mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P (TFA) [CAS 2828433-10-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012A-25mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P (TFA) [CAS 2828433-10-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012A-5mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P (TFA) [CAS 2828433-10-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012-1mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P [CAS 110880-55-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012-10mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P [CAS 110880-55-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-P1012-25mg
|
MedChemexpress LLC
|
[Sar9,Met(O2)11]-Substance P [CAS 110880-55-2]
|
|
Neuroscience-Neuromodulation
|
|
